APYX Stock Overview
An energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Apyx Medical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.41 |
| 52 Week High | US$2.76 |
| 52 Week Low | US$0.97 |
| Beta | 1.25 |
| 1 Month Change | -9.03% |
| 3 Month Change | -7.24% |
| 1 Year Change | -44.05% |
| 3 Year Change | -86.14% |
| 5 Year Change | -81.99% |
| Change since IPO | -57.03% |
Recent News & Updates
Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)?
Dec 19
Apyx Medical Corporation (NASDAQ:APYX) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Nov 23Recent updates
Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)?
Dec 19Apyx Medical Corporation (NASDAQ:APYX) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Nov 23Is There An Opportunity With Apyx Medical Corporation's (NASDAQ:APYX) 41% Undervaluation?
Sep 14Apyx Medical Corporation (NASDAQ:APYX) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 07We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed
Aug 01Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?
Jun 19Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive
Apr 18Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates
Mar 26Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)
Feb 16Is Apyx Medical (NASDAQ:APYX) A Risky Investment?
Sep 14Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?
Jun 07Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically
Mar 21Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation
Dec 14We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate
Aug 30Shareholder Returns
| APYX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.1% | -0.9% | 0.2% |
| 1Y | -44.0% | 12.5% | 22.0% |
Return vs Industry: APYX underperformed the US Medical Equipment industry which returned 12.5% over the past year.
Return vs Market: APYX underperformed the US Market which returned 22% over the past year.
Price Volatility
| APYX volatility | |
|---|---|
| APYX Average Weekly Movement | 14.5% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: APYX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: APYX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 252 | Charlie Goodwin | apyxmedical.com |
Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.
Apyx Medical Corporation Fundamentals Summary
| APYX fundamental statistics | |
|---|---|
| Market cap | US$52.33m |
| Earnings (TTM) | -US$28.44m |
| Revenue (TTM) | US$48.54m |
1.1x
P/S Ratio-1.9x
P/E RatioIs APYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APYX income statement (TTM) | |
|---|---|
| Revenue | US$48.54m |
| Cost of Revenue | US$19.22m |
| Gross Profit | US$29.33m |
| Other Expenses | US$57.77m |
| Earnings | -US$28.44m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 60.41% |
| Net Profit Margin | -58.59% |
| Debt/Equity Ratio | 302.3% |
How did APYX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 23:37 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Apyx Medical Corporation is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sam Eiber | BTIG |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| David Turkaly | JMP Securities |